Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > IGMS IGM Biosciences > Company Executives
IGMS IGM Biosciences
20.920
-0.080-0.38%
Post Mkt Price
20.9200.0000.00%
NamePositionSalaryService DateEducationAgeGenderUpdated
Mr. Fred SchwarzerDirector, Chief Executive Officer and President9.88M----70male04/27/2022
Mr. Chris H. Takimoto, M.D.Chief Medical Officer8.46M----63male04/27/2022
Ms. Lisa Lynn DeckerChief Business Officer4.86M----53female04/27/2022
Dr. Bruce Keyt, PhDChief Scientific Officer352.22K----69male04/27/2022
Mr. Misbah TahirChief Financial Officer------47male06/01/2022
Mr. George GauthierChief Commercial Officer------50male04/27/2022
Mr. Steven WeberPrincipal Accounting Officer, Senior Vice President and Corporate Controller------46male06/01/2022
Dr. Michael D. Loberg,PhDChairman of the Board476.31K----74male04/27/2022
Dr. M. Kathleen Behrens Wilsey, PhDIndependent Director453.62K----69female04/27/2022
Dr. Felix J. Baker,PhDIndependent Director440.79K----53male04/27/2022
Dr. Julie Hambleton, M.D.Independent Director457.31K----64female04/27/2022
Mr. Michael LeeIndependent Director432.96K----43male04/27/2022
Dr. William Strohl, PhDIndependent Director469.81K----69male04/27/2022
Ms. Christina Teng TopsoeIndependent Director449.54K----41female04/27/2022
Mr. Jakob Haldor TopsoeIndependent Director432.96K----53male04/27/2022
Company Overview More
IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. It offers the IgM platform to expand upon the inherent properties of IgM antibodies and to allow for the rapid development of engineered therapeutic antibodies. The firm’s product pipeline includes IGM-2323, which is a CD20 x CD3 bispecific IgM antibody designed to treat patients with B cell Non-Hodgkin's lymphoma and other B cell malignancies, IGM-8444, which is an IgM antibody targeting Death Receptor 5 for the treatment of patients with solid and hematologic malignancies, and IGM-7354, which will target the delivery of IL-15 with the goal of inducing immune cell stimulation and proliferation. The company was founded in 2010 and is headquartered in Mountain View, CA.
CEO: Mr. Fred Schwarzer
Market: NASDAQ
Listing Date: 09/18/2019
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist